Selected research
Industry Research
Lysosomal Alpha Glucosidase Industry Research Report 2026
Market perspective
The global Lysosomal Alpha Glucosidase market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Lysosomal Alpha Glucosidase is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Lysosomal Alpha Glucosidase is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Lysosomal Alpha Glucosidase is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Lysosomal Alpha Glucosidase include Sarepta Therapeutics Inc, Pharming Group NV, Oxyrane Belgium NV, JCR Pharmaceuticals Co Ltd, Huons Co Ltd, greenovation Biotech GmbH, Genzyme Corp, Etubics Corp and Audentes Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Lysosomal Alpha Glucosidase market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lysosomal Alpha Glucosidase Market by Company
Sarepta Therapeutics Inc
Pharming Group NV
Oxyrane Belgium NV
JCR Pharmaceuticals Co Ltd
Huons Co Ltd
greenovation Biotech GmbH
Genzyme Corp
Etubics Corp
Audentes Therapeutics Inc
Amicus Therapeutics Inc
Lysosomal Alpha Glucosidase Segment by Type
AT-982
ATB-200
AVRRD-03
JR-162
MOSS-GAA
OXY-2810
Others
Lysosomal Alpha Glucosidase Segment by Application
Glycogen Storage Disease
Pompe Disease
Others
Lysosomal Alpha Glucosidase Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lysosomal Alpha Glucosidase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lysosomal Alpha Glucosidase and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lysosomal Alpha Glucosidase.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Lysosomal Alpha Glucosidase manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Lysosomal Alpha Glucosidase by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Lysosomal Alpha Glucosidase in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- AT-982
- ATB-200
- AVRRD-03
- JR-162
- MOSS-GAA
- OXY-2810
- Others
Applications
- Glycogen Storage Disease
- Pompe Disease
- Others
Companies covered
- Sarepta Therapeutics Inc
- Pharming Group NV
- Oxyrane Belgium NV
- JCR Pharmaceuticals Co Ltd
- Huons Co Ltd
- greenovation Biotech GmbH
- Genzyme Corp
- Etubics Corp
- Audentes Therapeutics Inc
- Amicus Therapeutics Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Lysosomal Alpha Glucosidase Market Size (2021-2032)
- 2.2.2 Global Lysosomal Alpha Glucosidase Sales (2021-2032)
- 2.2.3 Global Lysosomal Alpha Glucosidase Market Average Price (2021-2032)
- 2.3 Lysosomal Alpha Glucosidase by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 AT-982
- 2.3.3 ATB-200
- 2.3.4 AVRRD-03
- 2.3.5 JR-162
- 2.3.6 MOSS-GAA
- 2.3.7 OXY-2810
- 2.3.8 Others
- 2.4 Lysosomal Alpha Glucosidase by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Glycogen Storage Disease
- 2.4.3 Pompe Disease
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Lysosomal Alpha Glucosidase Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Lysosomal Alpha Glucosidase Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Lysosomal Alpha Glucosidase Revenue of Manufacturers (2021-2026)
- 3.4 Global Lysosomal Alpha Glucosidase Average Price by Manufacturers (2021-2026)
- 3.5 Global Lysosomal Alpha Glucosidase Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Lysosomal Alpha Glucosidase, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Lysosomal Alpha Glucosidase, Product Type & Application
- 3.8 Global Manufacturers of Lysosomal Alpha Glucosidase, Established Date
- 3.9 Global Lysosomal Alpha Glucosidase Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sarepta Therapeutics Inc
- 4.1.1 Sarepta Therapeutics Inc Company Information
- 4.1.2 Sarepta Therapeutics Inc Business Overview
- 4.1.3 Sarepta Therapeutics Inc Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sarepta Therapeutics Inc Lysosomal Alpha Glucosidase Product Portfolio
- 4.1.5 Sarepta Therapeutics Inc Recent Developments
- 4.2 Pharming Group NV
- 4.2.1 Pharming Group NV Company Information
- 4.2.2 Pharming Group NV Business Overview
- 4.2.3 Pharming Group NV Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pharming Group NV Lysosomal Alpha Glucosidase Product Portfolio
- 4.2.5 Pharming Group NV Recent Developments
- 4.3 Oxyrane Belgium NV
- 4.3.1 Oxyrane Belgium NV Company Information
- 4.3.2 Oxyrane Belgium NV Business Overview
- 4.3.3 Oxyrane Belgium NV Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Oxyrane Belgium NV Lysosomal Alpha Glucosidase Product Portfolio
- 4.3.5 Oxyrane Belgium NV Recent Developments
- 4.4 JCR Pharmaceuticals Co Ltd
- 4.4.1 JCR Pharmaceuticals Co Ltd Company Information
- 4.4.2 JCR Pharmaceuticals Co Ltd Business Overview
- 4.4.3 JCR Pharmaceuticals Co Ltd Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 JCR Pharmaceuticals Co Ltd Lysosomal Alpha Glucosidase Product Portfolio
- 4.4.5 JCR Pharmaceuticals Co Ltd Recent Developments
- 4.5 Huons Co Ltd
- 4.5.1 Huons Co Ltd Company Information
- 4.5.2 Huons Co Ltd Business Overview
- 4.5.3 Huons Co Ltd Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Huons Co Ltd Lysosomal Alpha Glucosidase Product Portfolio
- 4.5.5 Huons Co Ltd Recent Developments
- 4.6 greenovation Biotech GmbH
- 4.6.1 greenovation Biotech GmbH Company Information
- 4.6.2 greenovation Biotech GmbH Business Overview
- 4.6.3 greenovation Biotech GmbH Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 greenovation Biotech GmbH Lysosomal Alpha Glucosidase Product Portfolio
- 4.6.5 greenovation Biotech GmbH Recent Developments
- 4.7 Genzyme Corp
- 4.7.1 Genzyme Corp Company Information
- 4.7.2 Genzyme Corp Business Overview
- 4.7.3 Genzyme Corp Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Genzyme Corp Lysosomal Alpha Glucosidase Product Portfolio
- 4.7.5 Genzyme Corp Recent Developments
- 4.8 Etubics Corp
- 4.8.1 Etubics Corp Company Information
- 4.8.2 Etubics Corp Business Overview
- 4.8.3 Etubics Corp Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Etubics Corp Lysosomal Alpha Glucosidase Product Portfolio
- 4.8.5 Etubics Corp Recent Developments
- 4.9 Audentes Therapeutics Inc
- 4.9.1 Audentes Therapeutics Inc Company Information
- 4.9.2 Audentes Therapeutics Inc Business Overview
- 4.9.3 Audentes Therapeutics Inc Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Audentes Therapeutics Inc Lysosomal Alpha Glucosidase Product Portfolio
- 4.9.5 Audentes Therapeutics Inc Recent Developments
- 4.10 Amicus Therapeutics Inc
- 4.10.1 Amicus Therapeutics Inc Company Information
- 4.10.2 Amicus Therapeutics Inc Business Overview
- 4.10.3 Amicus Therapeutics Inc Lysosomal Alpha Glucosidase Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Amicus Therapeutics Inc Lysosomal Alpha Glucosidase Product Portfolio
- 4.10.5 Amicus Therapeutics Inc Recent Developments
5 Global Lysosomal Alpha Glucosidase Market Scenario by Region
- 5.1 Global Lysosomal Alpha Glucosidase Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Lysosomal Alpha Glucosidase Sales by Region: 2021-2032
- 5.2.1 Global Lysosomal Alpha Glucosidase Sales by Region: 2021-2026
- 5.2.2 Global Lysosomal Alpha Glucosidase Sales by Region: 2027-2032
- 5.3 Global Lysosomal Alpha Glucosidase Revenue by Region: 2021-2032
- 5.3.1 Global Lysosomal Alpha Glucosidase Revenue by Region: 2021-2026
- 5.3.2 Global Lysosomal Alpha Glucosidase Revenue by Region: 2027-2032
- 5.4 North America Lysosomal Alpha Glucosidase Market Facts & Figures by Country
- 5.4.1 North America Lysosomal Alpha Glucosidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Lysosomal Alpha Glucosidase Sales by Country (2021-2032)
- 5.4.3 North America Lysosomal Alpha Glucosidase Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Lysosomal Alpha Glucosidase Market Facts & Figures by Country
- 5.5.1 Europe Lysosomal Alpha Glucosidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Lysosomal Alpha Glucosidase Sales by Country (2021-2032)
- 5.5.3 Europe Lysosomal Alpha Glucosidase Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Lysosomal Alpha Glucosidase Market Facts & Figures by Country
- 5.6.1 Asia Pacific Lysosomal Alpha Glucosidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Lysosomal Alpha Glucosidase Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Lysosomal Alpha Glucosidase Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Lysosomal Alpha Glucosidase Market Facts & Figures by Country
- 5.7.1 South America Lysosomal Alpha Glucosidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Lysosomal Alpha Glucosidase Sales by Country (2021-2032)
- 5.7.3 South America Lysosomal Alpha Glucosidase Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Lysosomal Alpha Glucosidase Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Lysosomal Alpha Glucosidase Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Lysosomal Alpha Glucosidase Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Lysosomal Alpha Glucosidase Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Lysosomal Alpha Glucosidase Sales by Type (2021-2032)
- 6.1.1 Global Lysosomal Alpha Glucosidase Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Lysosomal Alpha Glucosidase Sales Market Share by Type (2021-2032)
- 6.2 Global Lysosomal Alpha Glucosidase Revenue by Type (2021-2032)
- 6.2.1 Global Lysosomal Alpha Glucosidase Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Lysosomal Alpha Glucosidase Revenue Market Share by Type (2021-2032)
- 6.3 Global Lysosomal Alpha Glucosidase Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Lysosomal Alpha Glucosidase Sales by Application (2021-2032)
- 7.1.1 Global Lysosomal Alpha Glucosidase Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Lysosomal Alpha Glucosidase Sales Market Share by Application (2021-2032)
- 7.2 Global Lysosomal Alpha Glucosidase Revenue by Application (2021-2032)
- 7.2.1 Global Lysosomal Alpha Glucosidase Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Lysosomal Alpha Glucosidase Revenue Market Share by Application (2021-2032)
- 7.3 Global Lysosomal Alpha Glucosidase Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Lysosomal Alpha Glucosidase Value Chain Analysis
- 8.1.1 Lysosomal Alpha Glucosidase Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Lysosomal Alpha Glucosidase Production Mode & Process
- 8.2 Lysosomal Alpha Glucosidase Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Lysosomal Alpha Glucosidase Distributors
- 8.2.3 Lysosomal Alpha Glucosidase Customers
9 Global Lysosomal Alpha Glucosidase Analyzing Market Dynamics
- 9.1 Lysosomal Alpha Glucosidase Industry Trends
- 9.2 Lysosomal Alpha Glucosidase Industry Drivers
- 9.3 Lysosomal Alpha Glucosidase Industry Opportunities and Challenges
- 9.4 Lysosomal Alpha Glucosidase Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst